Evidence map›Paper›PMID 38418121›Full record

ArticleIn vivo (Athens, Greece)

The Naples Prognostic Score Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Aya Kato, Itaru Hashimoto, Yukio Maezawa, Kentaro Hara, Keisuke Kazama, Keisuke Komori, Hiroshi Tamagawa, Ayako Tamagawa, Shinsuke Nagasawa and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
Aya Kato *Department of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan; itarum1n1@hotmail.com.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KomoriDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinsuke NagasawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Haruhiko ChoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kenki SegamiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masato NakazonoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki OtaniDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Sho SawazakiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masakatsu NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Natsumi KamiyaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Suzue YoshizawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinnosuke KawaharaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study aimed to evaluate the clinical impact of the Naples Prognostic Score (NPS) in patients with gastric cancer and to clarify the potential of the NPS as a nutritional and inflammation evaluation system. PATIENTS AND

methodsThis study included 158 patients who underwent curative treatment for gastric cancer between 2005 and 2020. The prognosis and clinical pathological parameters of the high-NPS (NPS >2) and low-NPS (NPS=0, 1) groups were analyzed.

resultsThe overall survival (OS) rates at 3 and 5 years were 86.7% and 77.7%, respectively, in the low-NPS group and 55.4% and 47.4%, respectively, in the high-NPS group. There were significant differences in OS between the two groups. Uni- and multivariate analyses demonstrated that the NPS was an independent prognostic factor for OS (HR=2.495, 95%CI=1.240-5.451). In addition, the 3- and 5-year recurrence-free survival (RFS) rates were 82.1% and 76.0%, respectively, in the NPS-low group, and 43.8% and 36.6% in the NPS-high group. Univariate and multivariate analyses demonstrated that the NPS was an independent prognostic factor for RFS (HR=2.739, 95%CI=1.509-4.972). When the first site of recurrence was compared between the low-NPS group and high-NPS group, there were significant differences in peritoneal recurrence (8.7% vs. 34.3%, p=0.001) and hematologic recurrence (5.6% vs. 21.9%, p=0.004).

conclusionThe NPS was a significant prognostic factor in patients with gastric cancer who received curative treatment. The NPS may be a promising biomarker for the treatment and management of gastric cancer.

Indexed as

Stomach NeoplasmsHumansInflammationPeritoneumPrognosisRetrospective StudiesSurvival Ratebiomarkercurative treatmentgastric cancerNaples Prognostic Score

Identifiers

PMID38418121
PMCPMC10905489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.